Galapagos selects second component of its investigational cystic fibrosis combination treatment

  • Novel corrector GLPG2222 together with potentiator GLPG1837 offers therapy for most CF patients, potentially superior to current therapies under development
  • Start of Phase 1 with first novel corrector expected before end 2015
  • Final component for triple combination therapy expected to be nominated in 2015

Galapagos NV announced today that it nominated a first pre-clinical candidate corrector GLPG2222 for clinical development in its cystic fibrosis (CF) program. This corrector, in combination with GLPG1837, forms the core of Galapagos’ future combination therapy for the most common mutation in cystic fibrosis. The Galapagos combination has shown higher efficacy in pre-clinical studies than other therapies currently under clinical development.

Identification of novel, potent,¬†and efficacious corrector candidates is part of building a triple combination therapy with Galapagos’ potentiator GLPG1837, currently entering Phase 1 safety studies. Galapagos and AbbVie have developed multiple, novel correctors that in triple combination with GLPG1837, show >40% restoration of healthy (WT CFTR) activity in cells derived from CF patients with the delF508 mutation. Furthermore, the Galapagos-AbbVie corrector series compounds show good drug-like properties, which support further pre-clinical development. From these series, Galapagos selected a first pre-clinical candidate, the first corrector building block which together with potentiator GLPG1837, forms a solid basis for future triple combination developments. Galapagos is entering Phase 1 with GLPG1837 this month.

“Galapagos and AbbVie have five different chemical series with several excellent compounds from which to choose its novel CF correctors. The novel corrector nominated today forms the second of three ingredients needed for building our triple combination therapy. This selection brings us a big step closer to realizing our ambition of developing novel and best-in-class therapies for CF. The Galapagos-AbbVie team is working on selecting a second corrector candidate from our series to augment further the CFTR delF508 levels obtained by the dual GLPG1837/corrector combination,” said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos.

Galapagos initiated its research in CF in 2005. In September 2013 Galapagos signed an agreement with AbbVie in which they will work collaboratively to develop and commercialize oral drugs that address the main mutations in CF patients, including F508del and G551D.

Read the original story http://globenewswire.com/news-release/2014/12/12/690702/10112150/en/Galapagos-selects-second-component-of-its-investigational-cystic-fibrosis-combination-treatment.html which was published on 12th December 2014.

Leave a Reply